Definitive Healthcare (DH) Set to Release Quarterly Earnings on Thursday

Definitive Healthcare (NASDAQ:DH) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $54.57 million for the quarter. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings results on Monday, August 10th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.04 by $0.01. The firm had revenue of $55.20 million during the quarter, compared to analysts’ expectations of $55.47 million. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%. On average, analysts expect Definitive Healthcare to post $0.06 EPS for the current fiscal year and $0.04 EPS for the next fiscal year.

Definitive Healthcare Stock Up 3.2%

DH stock opened at $1.14 on Thursday. Definitive Healthcare has a 1-year low of $0.61 and a 1-year high of $3.00. The business’s 50 day simple moving average is $0.96 and its 200 day simple moving average is $1.11. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of 0.81. The firm has a market capitalization of $121.69 million, a PE ratio of -0.71, a PEG ratio of 13.33 and a beta of 1.40.

Analyst Ratings Changes

Several analysts recently commented on the company. Morgan Stanley reduced their target price on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $1.00 target price on shares of Definitive Healthcare in a research report on Wednesday, August 12th. BTIG Research reaffirmed a “neutral” rating on shares of Definitive Healthcare in a report on Friday, September 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Monday, August 31st. Finally, Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $1.47.

About Definitive Healthcare

Definitive Healthcare Corp. (NASDAQ: DH) provides data, analytics and commercial intelligence solutions for the healthcare industry. Its platform is designed to help organizations understand healthcare markets, identify business opportunities and make data-driven decisions.

The company serves pharmaceutical and biotechnology companies, medical device manufacturers, healthcare providers, hospitals and health systems, and other healthcare services organizations. Its offerings include information on healthcare providers and organizations, market intelligence, sales and marketing analytics, clinical trial insights, and tools that support commercial planning, market access and customer engagement.

Definitive Healthcare was founded in 2011 and became a publicly traded company in 2021.